Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
| Status: | Completed |
|---|---|
| Conditions: | Neurology, Orthopedic, Orthopedic |
| Therapuetic Areas: | Neurology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 60 - Any |
| Updated: | 12/12/2018 |
| Start Date: | September 16, 2014 |
| End Date: | October 25, 2018 |
A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
The purpose of this study is to assess if bimagrumab is safe and effective in patients with
muscle wasting (atrophy) after hip fracture surgery.
muscle wasting (atrophy) after hip fracture surgery.
Inclusion Criteria:
Must have X-ray confirmed successful hip fracture repair; must have completed surgical
wound healing; ability to walk a specified distance with or without a walking aid; must
weigh at least 35 kg.
Exclusion Criteria:
Must not have history of any other lower limb fractures in the past 6 months; Must not have
certain cardiovascular conditions; Must not have a chronic active infection (e.g. HIV,
hepatitis B or C, etc); Must not have used high-dose corticosteroid medications for at
least 3 months in the past year; Other protocol-defined inclusion and exclusion criteria
may apply.
We found this trial at
7
sites
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials